Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind cross-over study of glycopyrrolate pMDI in moderate to severe COPD
2010-018668-18Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Bronchodilator efficacy after single and repeated dosing (Part I) and Safety after single and repeated dosing (Part I). Started May 2010; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-018668-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018668-18.